There is wide variation in the survival of patients whose prognosis is determined using the American Joint Committee on Cancer (AJCC) staging system. A study in 3,728 patients who underwent surgery as first-line treatment has shown that the inclusion of pathologic stage, grade and estrogen receptor status improves the current AJCC staging system; these results were also confirmed in an external validation cohort. These findings indicate that the AJCC staging system should be revised to incorporate these three biologic markers.
ORIGINAL RESEARCH PAPER
Yi, M. et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer Staging System. J. Clin. Oncol. doi:10.1200/JCO.2011.38.3174
Rights and permissions
About this article
Cite this article
Improving the AJCC staging system. Nat Rev Clin Oncol 9, 4 (2012). https://doi.org/10.1038/nrclinonc.2011.187
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.187